{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:27:13Z","timestamp":1785403633870,"version":"3.56.0"},"reference-count":47,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"CAPES","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Tafenoquine (TQ) is a new 8-aminoquinoline antimalarial drug developed by the US Army for Plasmodium vivax malaria treatment. Modeling and simulation are essential tools for drug development and improving rationality in pharmacotherapy, and different modeling approaches are used. This study aims to summarize and explore the pharmacokinetic (PK) models available for tafenoquine in the literature. An integrative methodology was used to collect and review published data. Fifteen articles were identified using three modeling approaches: non-compartmental analysis (NCA), population pharmacokinetic analysis (popPK), and pharmacokinetic\/pharmacodynamic analysis (PK\/PD). An NCA was mainly used to describe the PK profile of TQ and to compare its PK profile alone to those obtained in association with other drugs. PopPK was used to assess TQ population PK parameters, covariates\u2019 impact, and dose selection. PK\/PD helped understand the relationship between TQ concentrations, some adverse events common for 8-aminoquilones, and the efficacy assessment for Plasmodium falciparum. In summary, pharmacokinetic models were widely used during TQ development. However, there is still a need for different modeling approaches to support further therapeutic questions, such as treatment for special populations and potential drug\u2013drug interactions.<\/jats:p>","DOI":"10.3390\/pharmaceutics16091124","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T04:48:25Z","timestamp":1724647705000},"page":"1124","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetic Models of Tafenoquine: Insights for Optimal Malaria Treatment Strategies"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8851-3438","authenticated-orcid":false,"given":"Luisa Oliveira","family":"Santos","sequence":"first","affiliation":[{"name":"Laboratory of Pharmacokinetics and Pharmacometrics, Faculty of Pharmacy, Federal University of Bahia, Salvador 40170-110, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabel Almeida","family":"Alves","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacokinetics and Pharmacometrics, Faculty of Pharmacy, Federal University of Bahia, Salvador 40170-110, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3625-0186","authenticated-orcid":false,"given":"Francine Johansson","family":"Azeredo","sequence":"additional","affiliation":[{"name":"Center for Pharmacometrics & System Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL 32827, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,26]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (WHO) (2023). WHO Guidelines for Malaria, WHO. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/373339\/WHO-UCN-GMP-2023.01-Rev.1-eng.pdf."},{"key":"ref_2","unstructured":"World Health Organization (WHO) (2023). World Malaria Report 2023, WHO. Available online: https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2023."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s13318-016-0399-1","article-title":"A review of pharmacogenetics of antimalarials and associated clinical implications","volume":"42","author":"Elewa","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Hossain, M.S., Matin, M.A., Ferdous, N.E.N., Hasan, A., Sazed, S.A., Neogi, A.K., Chakma, S., Islam, M.A., Khan, A.A., and Haque, M.E. (2023). Adherence to anti-malarial treatment in malaria endemic areas of Bangladesh. Pathogens, 12.","DOI":"10.3390\/pathogens12121392"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1590\/0037-8682-0275-2015","article-title":"Factors associated with non-adherence to the treatment of vivax malaria in a rural community from the Brazilian Amazon Basin","volume":"49","author":"Almeida","year":"2016","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1128\/AAC.42.5.1293","article-title":"Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial","volume":"42","author":"Brueckner","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"645","DOI":"10.4269\/ajtmh.1998.58.645","article-title":"First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial","volume":"58","author":"Brueckner","year":"1998","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1128\/CMR.00011-19","article-title":"8-aminoquinoline therapy for latent malaria","volume":"32","author":"Baird","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.2147\/DDDT.S61443","article-title":"Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: The evidence to date","volume":"26","author":"Ebstie","year":"2016","journal-title":"Drug Des. Devel Ther."},{"key":"ref_10","first-page":"10","article-title":"Pharmacometrics: A new era of pharmacotherapy and drug development in low- and middle-income countries","volume":"2023","author":"Usman","year":"2023","journal-title":"Adv. Pharmacol. Pharm. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.12793\/tcp.2019.27.1.19","article-title":"Evolving role of modeling and simulation in drug development","volume":"27","author":"Lim","year":"2019","journal-title":"Transl. Clin. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1365-2648.2005.03621.x","article-title":"The integrative review: Updated methodology","volume":"52","author":"Whittemore","year":"2005","journal-title":"J. Adv. Nurs."},{"key":"ref_13","first-page":"9","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1128\/AAC.00343-15","article-title":"Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics","volume":"59","author":"Voung","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1475-2875-13-141","article-title":"Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections","volume":"13","author":"Li","year":"2014","journal-title":"Malar. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7321","DOI":"10.1128\/AAC.01588-16","article-title":"Pharmacokinetic interactions between tafenoquine and dihydroartemisinin-piperaquine or artemether-lumefantrine in healthy adult subjects","volume":"60","author":"Green","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","first-page":"19","article-title":"Safety, pharmacokinetics, and potential neurological interactions of ivermectin, tafenoquine, and chloroquine in Rhesus macaques","volume":"68","author":"Vanachayangkul","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/bcp.12160","article-title":"Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects","volume":"76","author":"Miller","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/jcph.302","article-title":"Tafenoquine at therapeutic concentrations does not prolong Fridericia-corrected QT interval in healthy subjects","volume":"54","author":"Green","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1093\/cid\/ciad075","article-title":"Characterizing the blood-stage antimalarial activity of tafenoquine in healthy volunteers experimentally infected with Plasmodium falciparum","volume":"76","author":"Barber","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1023\/A:1015842316177","article-title":"Simultaneous modeling of the pharmacokinetics and methemoglobin pharmacodynamics of an 8-aminoquinoline candidate antimalarial (WR 238605)","volume":"8","author":"Brueckner","year":"1991","journal-title":"Pharm. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.1128\/AAC.00718-15","article-title":"Exposure-response analyses for tafenoquine after administration to patients with Plasmodium vivax malaria","volume":"59","author":"Tenero","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1128\/AAC.00711-18","article-title":"Population pharmacokinetics of tafenoquine, a novel antimalarial","volume":"62","author":"Thakkar","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1046\/j.0306-5251.2001.01482.x","article-title":"Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers","volume":"52","author":"Edstein","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1128\/AAC.01183-06","article-title":"Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects","volume":"51","author":"Charles","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/bcp.15554","article-title":"A Pharmacometrics approach to assess the feasibility of capillary microsampling to replace venous sampling in clinical studies: Tafenoquine study","volume":"89","author":"Bachhav","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S2352-4642(21)00328-X","article-title":"Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: Open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial","volume":"6","author":"Hien","year":"2022","journal-title":"Lancet Child. Adolesc. Health"},{"key":"ref_28","unstructured":"Shargel, L., and Yu, A.B.C. (2016). Empirical models, mechanistic models, statistical moments, and noncompartmental analysis. Applied Biopharmaceutics and Pharmacokinetics, Mc Graw Hill Education. [7th ed.]."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/978-1-62703-050-2_16","article-title":"Non-compartmental analysis","volume":"929","author":"Gabrielsson","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"ref_30","unstructured":"Gibaldi, M., and Perrier, M. (2007). Noncompartmental analysis based on statistical moment theory. Pharmacokinetics, Informa Healthcare. [2nd ed.]."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Ojara, F.W., Kawuma, A.N., and Waitt, C. (2023). A systematic review on maternal-to-infant transfer of drugs through breast milk during the treatment of malaria, tuberculosis, and neglected tropical diseases. PLoS Negl. Trop. Dis., 17.","DOI":"10.1371\/journal.pntd.0011449"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0924-8579(02)00022-5","article-title":"Animal model pharmacokinetics and pharmacodynamics: A critical review","volume":"4","author":"Andes","year":"2002","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Pasquiers, B., Benamara, S., Felices, M., Nguyen, L., and Decl\u00e8ves, X. (2022). Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232112754"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/bod.2510090602","article-title":"The potential role of lysosomes in tissue distribution of weak bases","volume":"9","author":"MacIntyre","year":"1988","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jcph.1633","article-title":"Parametric approaches in population pharmacokinetics","volume":"62","author":"Guidi","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2165\/00003088-199732040-00003","article-title":"Role of population pharmacokinetics in drug development: A pharmaceutical industry perspective","volume":"32","author":"Samara","year":"1997","journal-title":"Clin. Pharmacokinet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/psp.2013.26","article-title":"Establishing best practices and guidance in population modeling: An experience with an internal population pharmacokinetic analysis guidance","volume":"2","author":"Byon","year":"2013","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2147\/IJN.S76317","article-title":"Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice","volume":"10","author":"Melariri","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Vinks, A.A., Mounton, J.W., and Derendorf, H. (2014). Principles of applied pharmacokinetic-pharmacodynamic modeling. Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics, Springer. [1st ed.].","DOI":"10.1007\/978-0-387-75613-4"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Mi, K., Zhou, K., Sun, L., Hou, Y., Ma, W., Xu, X., Huo, M., Liu, Z., and Huang, L. (2022). Application of semi-mechanistic pharmacokinetic and pharmacodynamic model in antimicrobial resistance. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14020246"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.drudis.2013.05.001","article-title":"The virtue of translational PKPD modeling in drug discovery: Selecting the right clinical candidate while sparing animal lives","volume":"18","author":"Bueters","year":"2013","journal-title":"Drug Discov. Today"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.drudis.2017.04.015","article-title":"Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: An IQ Consortium PK-PD Discussion Group perspective","volume":"22","author":"Wong","year":"2017","journal-title":"Drug Discov. Today"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1473-3099(07)70187-1","article-title":"Cardiotoxicity of antimalarial drugs","volume":"7","author":"White","year":"2007","journal-title":"Lancet Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Mzayek, F., Deng, H., Mather, F.J., Wasilevich, E.C., Liu, H., Hadi, C.M., Chansolme, D.H., A Murphy, H., Melek, B.H., and Tenaglia, A.N. (2007). Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin. Trials, 2.","DOI":"10.1371\/journal.pctr.0020006"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1517\/13543784.16.5.705","article-title":"Tafenoquine: A promising new antimalarial agent","volume":"16","author":"Crockett","year":"2007","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_46","first-page":"1","article-title":"Metabolism of a candidate 8-aminoquinoline antimalarial agent, WR 238605, by rat liver microsomes","volume":"23","author":"Idowu","year":"1995","journal-title":"Drug Metab. Dispos."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4269\/ajtmh.16-0779","article-title":"Hemolytic potential of tafenoquine in female volunteers heterozygous for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PD Mahidol variant) versus G6PD-normal volunteers","volume":"97","author":"Rueangweerayut","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/9\/1124\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:42:46Z","timestamp":1760110966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/9\/1124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":47,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["pharmaceutics16091124"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics16091124","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,26]]}}}